NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital leads $67.5 million (€64.4 million) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
Proceeds of financing will support two double-blinded Phase 2 trials for its lead candidate XC001, a pioneering transformative gene therapy approach for the treatment of severe cardiovascular disease. This investment builds on Jeito's expertise in cardiology,...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital co-leads $156million oversubscribed Series B financing in Quell Therapeutics
Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell...
Jeito Capital portfolio company SparingVision announces strategic collaboration with Intellia Therapeutics
Partnership will allow SparingVision to develop novel genomic medicines for the treatment of...
Jeito Capital becomes Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 million ($630 million)
Oversubscribed Jeito I becomes the largest European fund dedicatedto the life sciences sector....
Jeito Capital’s Dr. Rafaèle Tordjman Appointed to Promote the French Biotech Ecosystem
The appointment of Dr. Tordjman was granted by French Ministers, Agnès Pannier-Runacher and...
Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round
Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the fund...
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
Jeito selects Pulmocide as its fourth investment since launching the fund Pulmocide is a...
Face to face
Meet Jeito
16-17
December
All day long
Conference of Paris 2024
Jeito will be present at the Conference of Paris 2024, for its 8th edition around the theme “Confronting the Unknown”, encouraging leaders to share their knowledge and understanding of global economic, social and environmental issues as a way to collaborate and collectively overcome these challenges.
13-16
January
All day long
JPM Healthcare Conference 2025
Jeito will be present at the 43rd JPM Healthcare Conference 2025, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.
28-30
January
All day long
IPEM Cannes 2025
Jeito will be present at the 11th edition of IPEM Cannes – Wealth 2025, gathering Private Capital key decision-makers and incubating this year “IPEM Wealth”, a brand-new format designed to support the democratization of Private Markets, in Cannes.